Taken together, our data suggest that targeting the TGR5‐ERK1/2 pathway via bile acid modulation may represent a promising therapeutic strategy to ameliorate cognitive dysfunction associated with ADT treatment in prostate cancer. Here, MAPK3 is linked to prostate cancer.